GlycoNex Incorporation (TPEX:4168)
Taiwan · Delayed Price · Currency is TWD 29.40
+0.80 (2.80%)
Jan 21, 2026, 1:30 PM CST
GlycoNex Incorporation Revenue
GlycoNex Incorporation had revenue of 3.85M TWD in the quarter ending September 30, 2025, with 75.89% growth. This brings the company's revenue in the last twelve months to 36.63M, up 217.92% year-over-year. In the year 2024, GlycoNex Incorporation had annual revenue of 14.70M with 478.32% growth.
Revenue (ttm)
36.63M
Revenue Growth
+217.92%
P/S Ratio
86.84
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.70M | 12.16M | 478.32% |
| Dec 31, 2023 | 2.54M | -27.54M | -91.55% |
| Dec 31, 2022 | 30.09M | 24.61M | 449.50% |
| Dec 31, 2021 | 5.48M | 5.02M | 1,113.97% |
| Dec 31, 2020 | 451.00K | -283.00K | -38.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |
| Caliway Biopharmaceuticals | 34.99M |